



































Metabolic adaptation has emerged as a hallmark of 
cancer and a promising therapeutic target [1-9]. Rapidly 
proliferating cancer cells adapt their metabolism by 
increasing nutrient uptake and reorganizing metabolic 
fluxes to sustain biosynthesis of macromolecules 
necessary to achieve cell division and maintained redox 
and energy equilibrium [10-18]. It is increasingly 
evident that oncogenes and tumor suppressor genes 
regulate the metabolic rearrangement in cancer cells 
[19-23]. 
 
TAp73 acts as a tumor suppressor [24-27], at least 
partially through induction of cell cycle arrest and 
apoptosis [28] and through regulation of genomic 
stability [29, 30]. In addition, premature senescence is 
observed in TAp73 null mice suggesting that the 





































cence [31]. At least in part, this anti-senescence effect is 
mediated by a direct transcriptional effect of TAp73 on 
mitochondrial gene Cox4i1, hence regulating 
mitochondrial metabolism [31]. We also reported that 
TAp73 induces serine biosynthesis and glutaminolysis 
in lung cancer cells, via a direct transactivation of 
GLS2[32]. Interestingly, increased serine biosynthesis 
sustains cancer growth and has been recently reported to 
be nourished in breast cancer and melanoma by 
amplification of phosphoglycerate dehydrogenase gene 
[33, 34]. Recently, Du and colleagues [35, 36] reported 
that TAp73 triggers the expression of glucose-6-
phosphate dehydrogenase (G6PD), the rate-limiting 
enzyme of the pentose phosphate pathway (PPP), thus 
increasing flux through the PPP. By doing so, TAp73 
diverts glucose to the production of NADPH and ribose, 
promoting synthesis of nucleotides and contributing to 
scavenging of reactive oxygen species [37]. The authors 
also describes that depletion of TAp73 leads  to  defective 
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cellular proliferation, promptly rescued by G6PD 
expression or, alternatively, by addiction of nucleosides 
and ROS scavengers. Therefore, the authors conclude 
that TAp73 regulate metabolism with the ultimate result 
of promoting cell growth and proliferation, in striking 
contrast to its established role as tumor suppressor. 
 
Prompted by these findings, we attempted to elucidate 
the regulation of cellular metabolism and proliferation 
by TAp73 using high throughput metabolomics study 
upon ectopic expression of TAp73β isoform in human 
p53-null osteosarcoma cell lines (SaOs-2). Moreover, 
we validated in-vitro findings, in brain tissue from 
TAp73 null mice. Here, we report that TAp73 promotes 
anabolic metabolism and nucleotide biosynthesis. 
Moreover, our data suggest that TAp73 promotes 
glycolysis and enhances the Warburg effect. 
Nonetheless, these changes are unlikely to lead to cell 
proliferation, as accompanied by robust upregulation of 
the cell cycle inhibitor p21 and marked apoptosis. 
Therefore, based on these and other findings we 
propose that TAp73-mediated control of cellular 
metabolism should be interpreted on the light of its 
multifaceted physiological activities, especially in the 
context of regulation of animal aging, fertility and 
neurodegerative diseases[31, 38-41]. We suggest that 
TAp73 promotes a metabolic reprogramming that act to 
protect from accelerated senescence and aging, as 
previously demonstrated[31, 42]. This interpretation 
will reconcile the findings of Du and colleagues with 
the abundant literature attributing a tumour suppressive 




TAp73 activates anabolic pathways 
 
To investigate the effects of TAp73 expression on 
cellular metabolism, we used human p53/p73 null 
SaOs-2 osteosarcoma cell line, engineered to 
overexpress HA-tagged TAp73β isoform when cultured 
in the presence of the tetracycline analog doxycycline 
(Dox)[43] and used GC-MS and LC-MS-MS platforms 
to perform high throughput metabolomics [44]. With 
this approach, we unveiled an unexpected role for 
TAp73 in promoting the Warburg effect (manuscript in 
preparation). TAp73-expressing cells show an increased 
rate of glycolysis, higher amino acid uptake and 
increased levels and biosynthesis of acetyl-CoA 
(manuscript in preparation). Moreover, TAp73 
expression increases the activity of several anabolic 
pathways including polyamine and membrane 
phospholipid synthesis (manuscript in preparation). In 
addition, nucleotide biosynthesis was significantly 
upregulated by TAp73. The biochemical analysis of 
intracellular nucleotides content is shown in Figures 1 
and illustrates a sustained and significant upregulation 
of both purines and pyrimidines. Thus, our data indicate 
that TAp73 regulates multiple metabolic pathways that 
impinge on numerous cellular functions, but which, 
overall, converge to sustain “biochemical” cell growth 
and proliferation, in full agreement with the indicated 
report [35, 45].  
 
p73 induces cell cycle arrest and cell death 
 
Although the described findings might be interpreted as 
suggestive of pro-proliferative function for TAp73, a 
careful analysis of the cell cycle profile indicates the 
complete absence of TAp73-induced proliferation. 
Indeed, Figure 2 shows the cell cycle and the cell death 
analysis at different time points. Expression of TAp73 β 
C-terminal isoforms reached plateau after 16h of Dox 
treatment, without any discernible effect on cell cycle 
distribution (Figure 2C), except for a mild increased in 
the G1 phase at 72h post-induction. Notwithstanding, 
expression of TAp73β was accompanied by a robust 
upregulation of the cell cycle inhibitor p21, evident 
already 8h after Dox administration (Figure 2D), 
strongly arguing against a proliferative role for TAp73. 
As expected, at later time points, the cells underwent 
programmed cell death, as previously described for 
TAp73 [43, 46].  Of note, the timing of the 
metabolomic analysis (blue arrows) was deliberately 
chosen before the onset of cell death, to avoid any 
confusion arising from metabolic changes associated 
with apoptosis. Overall, these data suggest that, 
although TAp73 expression stimulates anabolic 
pathways, it is unlikely to promote cellular 
proliferation, due to upregulation of the cell cycle 
inhibitor p21 and induction of apoptosis. 
 
TAp73 depletion affects nucleotide metabolism in 
vivo 
 
Since TAp73 exerts a relevant role in the physiology of 
the nervous system [38, 47-49], we analyzed cerebral 
cortex and hippocampus isolated from TAp73 wild-type 
(WT) and knockout (KO) animals [50] to question 
whether TAp73 regulates nucleotides metabolism in-
vivo. Notably, in agreement with the in-vitro 
experiment, we found that purine metabolism was 
altered in TAp73KO brains. In particular, inosine and 
adenosine were significantly higher in the cortex of 
TAp73KO compared to WT controls. Moreover, 
allantoin, the final product in purine catabolism, was 
higher in both TAp73KO cortex and hippocampus, 
reaching statistical significance in the latter. On the 
other hand, inosine 5’- monophosphate and adenosine 
5’- monophosphate were significantly reduced in the 
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cortex and hippocampus of TAp73 KO mice, 









































































































Figure  1.  TAp73  overexpression  induces  nucleotide  monophosphates.  TAp73β
overxpression in SaOs‐2 Tet‐On cell lines results in a highly significant enrichment in all nucleotide
monophosphates,  consistent  with  an  increased  metabolic  demand  to  sustain  cell  growth.  (a)
adenosine 5’‐monophosphate  (AMP),  (b) guanosine 5’‐monophosphate  (5’‐GMP),  (c) cytidine 5’‐
monophosphate (5’‐CMP), (d) thymidine 5’‐monophosphate, (e) uridine monophosphate (5’ or 3’‐
UMP). Analysis was performed on thirty million cells per samples, 10 samples were analyzed for
each  time  point  (n=10).  All  the  samples  were  extracted  using  standard  metabolic  solvent
extraction methods  and  analyzed  through GC/MS  and  LS/MS  as previously described  [44]. Box
indicates upper/lower quartile, bars max/min of distribution.  ** p<0.05; * 0.05<p<0.10. 
  













































The identification of extensive metabolic re-
arrangements that sustain cancer growth has spurred 
interest towards a deeper understanding of the 
underpinning regulatory mechanisms [10, 19, 37, 51-
54]. It is widely implied that oncogenes reprogram 
metabolism to sustain cell growth, whereas tumor 















































regulation [19, 55, 56]. This network assumes a striking 
relevance in the case of p53, as impairing p53 family 
ability to trigger apoptosis [57-64], senescence [65-73] 
and cell-cycle arrest does not abolish its tumor 
suppressor efficacy [74-78], which apparently is 
maintained through regulation of metabolic genes[50, 
79-83]. This suggests that metabolism might have 
greater relevance than previously thought in repressing 
cellular transformation. 




evident  only  after  24h  of  TAp73  induction.  Data  indicate  average  of  triplicates  and  standard
deviation. Blue arrows  indicate  the  time points used  for metabolomics analysis  (same cultures as
shown  here).  (c)  Cell  cycle  profile  after  induction  of  TAp73β  determined  by  PI  staining  and
cytofluorimetric  analysis.  Controls  were  left  untreated  (0h)  or  treated  with  vehicle  for  72h  to
account  for  changes  induced  by  confluence.  Data  indicate  average  of  triplicates  and  standard
deviation.   Blue arrows  indicate  the time points used  for metabolomics analysis  (same cultures as
shown here).    (d) TAp73β and p21 expression were assessed by western blotting after  treatment



















































































































in  TAp73  knockout  (TA73KO)  versus wild‐type  (WT) mouse  cerebral  cortex  (C)  and  hippocampus  (H)  (n=8
biological littermate replicates; age 1 day). These are the two areas of the central nervous system that show
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TAp73 has been known as a tumor suppressor gene able 
to induce cell cycle arrest and apoptosis [30, 84] 
similarly to its sibling p53 [40, 85-91]. This view has 
been recently challenged by the finding that TAp73 
promotes cellular proliferation through the expression 
of the PPP enzyme G6PD and, therefore, diverts 
glucose metabolism towards PPP and production of 
NADPH for ROS detoxification and ribose for 
nucleotide biosynthesis and proliferation [35]. In the 
attempt to unravel the link between TAp73 and 
regulation of cellular metabolism, and to understand its 
association with the established tumor suppressor role 
of TAp73, we have performed metabolic analysis in-
vitro, in cells overexpressing TAp73β and in-vivo in 
mice depleted of TAp73. We did not observe evident 
differences in PPP, but we did record increase 
glycolytic rate in TAp73 expressing Saos-2 cells, 
together with augmented uptake of amino acids and 
increased biosynthesis of acetyl-CoA (manuscript in 
preparation). Moreover we observed a robust increased 
in intracellular content of nucleotides. Altered 
metabolism of nucleotides was also identified in in the 
cortex and hippocampus of TAp73 depleted mice, 
underlining the physiological relevance of TAp73-
mediated control of metabolism. These data are partially 
in agreement with the findings of Du and colleagues 
[35]. But the interpretation that TAp73 promotes 
proliferation [35] would represent a paradigm shift for 
the p53 family [40, 85, 92] and would hardly reconcile 
with the ability of TAp73 to regulate expression of the 
cell cycle inhibitor p21 and to induce apoptosis. Indeed, 
our data and work from other groups have consistently 
demonstrated that TAp73 does halt cell cycle and 
induce cell death in a variety of cells and in response to 
diverse stimuli, acting as a proper tumor suppressor [24, 
29, 43, 85, 92]. Therefore, we question whether the 
experimental data are sufficiently robust to support this 
change of dogma.  
 
On the other hand, we have recently demonstrated that 
TAp73 knockout mice are affected by an aging 
phenotype accompanied by decreased mitochondrial 
function, augmented intracellular ROS levels and 
sensitivity to oxidative stress [31]. These metabolic 
alterations ultimately converge in promoting accelerated 
senescence in vitro and aging in-vivo. Therefore, the 
regulation of cellular metabolism by TAp73 could be 
interpreted on the light of its anti-senescence and anti-
ageing function. This interpretation is reinforced by the 
finding that cellular senescence suppresses nucleotide 
metabolism [93, 94]. We could therefore envisage a 
scenario where TAp73 expression leads to cell cycle 
arrest or cell death, but promotes a metabolic rewiring 
that prevents normal cell from undergoing senescence, 
with possible important implication for neuronal 
development and neurodegenerative disease, on the light 
of TAp73 involvement in brain physiology [38, 95]. 
 
In summary, our interpretation of the apparent 
inconsistency, whereby TAp73 promotes “biochemical 
proliferation” and “cellular cell death”, inhibiting tumor 
progression, is that TAp73 counteracts cellular 
senescence by activating an anti-senescence metabolic 
response. 
 
MATERIALS AND METHODS 
 
Cells culture. SaOs-2 Tet-On inducible for TAp73 were 
cultured at 37 °C in 5% CO2 in RPMI 1640 medium 
(Gibco), supplemented with 10% FCS, 250 mM L-
glutamine, penicillin/streptomycin (1 U/ml), and 1 mM 
pyruvate (all from Life Technologies). TAp73 
expression was induced by addition of doxycycline 
(Sigma) 2μg/ml (stock 2mg/ml in PBS) for the 
indicated time. 
 
Western Blots. Proteins were extracted from cell pellets 
using RIPA buffer (25mM Tris/HCl pH 7.6, 150mM 
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) 
supplemented with phosphatase and protease inhibitor 
cocktails (ROCHE). Quantification of protein extracts 
was performed using BCA protein assay from PIERCE. 
40μg of protein were boiled for 6 minutes at 90°C and 
then separated using SDS-PAGE, transferred to 
nitrocellulose membranes using standard transfer 
techniques and blocked with 5% milk for 2h at room 
temperature. Primary antibodies were incubated O/N at 
4°C in blocking with gentle agitation. We used rabbit 
HA (Santa Cruz, Y11), rabbit β-tubulin (Santa Cruz, H-
135), rabbit p21 (H-164) and Alexis anti-PARP. 
Horseradish peroxidase (HRP)-conjugated secondary 
antibodies (BioRad) and ECL chemoluminescence 
substrate (PIERCE) were used for final detection. 
 
Metabolic analysis. TAp73 SaOs-2 Tet-On cell lines 
were cultured in growing medium and treated for 8h 
and 16h with doxycycline 2 μg/ml to induce TAp73β 
expression. Control cells were treated with vehicle 
(PBS) for 16h. Thirty million cells were spun down and 
pellets were washed once with cold PBS before being 
frozen in dry ice. All the samples were extracted using 
standard metabolic solvent extraction methods and 
analyzed through GC/MS and LS/MS as previously 
described [44]. After log transformation and imputation 
with minimum observed values for each group, the 
comparison of the metabolic compounds of the 
indicated samples was visualized. 
 
Cell cycle and survival. For cell cycle analysis 500,000 
cells were treated for the indicated time with 
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doxycycline 2μg/ml, collected and fixed with ice cold 
70% ethanol. After O/N fixing at -20°C, cells were 
washed in PBS, resuspended in 50μl of 10μg/ml RNase 
solution (SIGMA) and incubated for 10 minutes at 
37°C. 500μl of staining solution (50μg/ml propidium 
iodide in PBS) was added to the cells, followed by 
additional incubation 30 minutes at 37°C. Stained cells 
were analyzed by flow cytometry and at least 10,000 
cells per sample were collected. Data were analyzed 
using CELLQuest acquisition/analysis software. 
 
Mice. TAp73 null mice in C57BL6 background were 
genotyped as previously described [24]. For metabolic 
analysis cortex and hippocampus were removed from 1 
day old mice of both genotype and immediately frozen 
and stored at -80° C.  
 
The animal experiments were performed under project 
licenses PPL 40/3442, granted to MA by the UK 
Home Office. Animal husbandry and experimental 
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